Biocept (NASDAQ:BIOC) Research Coverage Started at initiated coverage on shares of Biocept (NASDAQ:BIOCFree Report) in a report issued on Friday. The firm issued a hold rating on the medical research company’s stock.

Biocept Stock Down 13.1 %

Shares of NASDAQ BIOC opened at $0.43 on Friday. The firm has a fifty day simple moving average of $1.00 and a two-hundred day simple moving average of $2.67. The firm has a market capitalization of $1.14 million, a PE ratio of -0.01 and a beta of 0.69. The company has a current ratio of 1.81, a quick ratio of 1.70 and a debt-to-equity ratio of 2.88. Biocept has a 12 month low of $0.32 and a 12 month high of $27.00.

Institutional Trading of Biocept

Several institutional investors and hedge funds have recently bought and sold shares of BIOC. Boothbay Fund Management LLC purchased a new position in shares of Biocept in the 2nd quarter valued at approximately $28,000. Renaissance Technologies LLC raised its holdings in Biocept by 27.1% in the first quarter. Renaissance Technologies LLC now owns 116,400 shares of the medical research company’s stock worth $270,000 after purchasing an additional 24,800 shares in the last quarter. Anson Funds Management LP purchased a new position in Biocept during the second quarter valued at $54,000. Finally, Millennium Management LLC bought a new stake in shares of Biocept during the 2nd quarter valued at $97,000.

About Biocept

(Get Free Report)

Biocept, Inc, a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms.

Featured Articles

Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with's FREE daily email newsletter.